Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/13/2021 | $12.00 | Buy | Brookline Capital |
| 6/29/2021 | $5.00 | Buy | Litchfield Hills |
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, "We made meaningful progress during the first quarter of 2025, completing foundational steps that position us to advance swiftly toward the initiation of our Phase 3 clinical trial for AD04, our lead investigational drug for Alcohol Use Disorder (AUD)." "One of the key ac
Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received a six-figure development milestone payment from Adovate, LLC, following the commencement of a Phase 1 clinical trial evaluating Adovate's lead compound for asthma, ADO-5030. This milestone payment follows Adovate's exercise of its option to acquire the assets and business of Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, as previously disclosed. The ongoing Phase 1 study
Meeting to Take Place on July 25, 2025 Meeting's Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial's request for an End of Phase 2 meeting to discuss Adial's proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00
Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities Adial in discussions with potential pharma partners Conference call to be held at 8:15 a.m. EST tomorrow CHARLOTTESVILLE, Va., March 06, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company") a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on its regulatory strategy for AD04, the Company's lead compound for the treatment of Alcohol Use Disorder (A
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Time, to provide an update on its regulatory and partnering strategy for the United States and Europe. The company will also present and discuss the findings from its subgroup analysis of ONWARD data. A live audio webcast of the conference call and accompanying slide presentation may be accessed at https
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call to be held today at 1:00 p.m. Eastern Time CHARLOTTESVILLE, Va., July 20, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-sta
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key Highlights Successful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron. Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership
GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We reached an important milestone this quarter with the successful database lock of the pharmacokinetics study for AD04, our lead investigational, genetically targeted therapeutic for the treatment of Alcohol Use Disorder (AUD). The pharmacokinetics study is e
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
S-1 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
S-3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)